Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMF8B62)

Drug Name

Linetastine Drug Info

Synonyms

Tmk688; UNII-7U248Z56LA; 110501-66-1; TMK-688; 159776-68-8; 7U248Z56LA; Linetastine [INN]; Tmk 688; Linazolast; CCRIS 6902; Linazolast (JAN); YM-257; AC1O5R98; CHEMBL314338; SCHEMBL1614484; [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; D09850; Linazolast; Molecule 26

Indication

Disease Entry	ICD 11	Status	REF
Rhinitis	FA20	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 6439232
CAS Number: CAS 110501-66-1
TTD Drug ID: DMF8B62

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 5-lipoxygenase (5-LOX)	TT2J34L	LOX5_HUMAN	Inhibitor	[2]
Protein kinase C beta (PRKCB)	TTYPXQF	KPCB_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Arachidonate 5-lipoxygenase (5-LOX)	DTT	ALOX5	4.966	5.133	5.358	6.128

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Rhinitis

ICD Disease Classification

FA20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Arachidonate 5-lipoxygenase (5-LOX)	DTT	ALOX5	4.15E-01	-0.06	-0.15

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002311)
2	Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45.
3	Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002 May;133(5):693-8.